|
Eli Lilly PET Drug Misbranded by Misleading Imagery, FDA Says
Eli Lilly has misbranded its radioactive PET drug Amyvid, approved for reviewing displays of brain scans using a black-and-white scale, by featuring a multi-colored brain image on a webpage advertisement and other promotional materials for the product, according to an FDA untitled letter.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives